Search

VS-5584 is a small-molecular compound that showed equivalent activity against mTOR and all class I PI3K isoforms and demonstrated preclinical activity in diverse cancer cell lines and xenograft tumor model, and rational combination of VS-5584 and other target therapies achieved promising outcomes in oncology. In the present study, we established and validated a simple and sensitive UPLC-MS/MS method for the determination of VS-5584 in plasma samples. VS-5584 was separated via an Acquity UPLC BEH C18 column, with a mobile phase composed of acetonitrile and 0.2% formic acid in water (40 : 60). The calibration curve displayed a good linearity in the range of 1.0–1000 ng/mL, with satisfactory accuracy (−13.6% < RE% < 8.8%) and precision (CV%, less than 9.2%). The validated method was then applied to a pharmacokinetic study in rats. After administration of 10 mg/kg, VS-5584 was absorbed quickly and reached a peak concentration of 473.2 ± 72.0 ng/mL after 20 min. The established method allows for the quantification of VS-5584 in rat plasma in detail and can be utilized to successfully describe the pharmacokinetic profile of VS-5584. [ABSTRACT FROM AUTHOR]

Cell surface receptors are important proteins that mediate communication between the cells and their outside environment, and also play essential roles in the control of a wide variety of biological processes, such as cell cycle, proliferation, communication, migration and apoptosis. Receptor oligomerization is an essential signal transduction mechanism that cell surface receptors use to transmit extracellular signals into the internal cytosol cellular machinery. Therefore, regulating receptor oligomerization provides an opportunity to customize cellular signaling and to direct cellular behavior in a user-defined manner. Some techniques have been developed for receptor oligomerization regulation, such as chemically induced dimerization (CID) and optogenetics, which involve traditional genetic engineering. However, the process of genetic manipulation is time-consuming, unpredictable and inefficient. Thus, development of nongenetic strategies for precisely regulating receptor oligomerization remains a desirable goal. Recently, along with the utilization of DNA, protein, small molecules and stimuli-responsive materials-based nongenetic engineering strategies, various receptor oligomerization and multiple cellular behaviors could be regulated, including migration, proliferation, apoptosis, differentiation and immune responses, etc. In this review, we aim to systematically introduce advances in the development of nongenetic engineering strategies for regulating receptor oligomerization, and provide insights into the existing challenges and future perspectives of this field. [ABSTRACT FROM AUTHOR]

Salvianolic acid A (SAA) is the main active component of the classic anti-atherosclerotic drug Salvia miltiorrhiza Bunge. Inflammation-induced infiltration of monocyte/macrophages into the vascular wall is the initiating step in atherogenesis, and targeted blocking of this step may provide a promising avenue for the precise treatment of atherosclerosis. However, the effect of salvianolic acid A on macrophages is still unknown. To evaluate the effect of SAA on macrophage infiltration and the underlying mechanism of SAA against atherosclerosis. Vascular endothelial cells were stimulated with lipopolysaccharide (LPS) to simulate the inflammatory environment, and its effect on monocyte/macrophages was evaluated. Mass spectrometry was used to identify the proteins that play a key role and further validated them. LncRNA sequencing, western blot analysis, RNA immunoprecipitation, and RNA pulldown were used to elucidate the mechanism of SAA against atherosclerosis. Finally, ApoE−/− mice were fed a high-fat diet to creat an in vivo atherosclerosis model. Secretory GRP78 content, lipid levels, plaque area, macrophage infiltration, and degree of inflammation were assessed by standard assays after 16 weeks of intragastric administration of SAA or biweekly tail vein injections of GRP78 antibody. After LPS stimulation, the increased secretion of GRP78 recruits circulating monocyte/macrophages and drives monocyte/macrophage adhesion and invasion into the vascular intima to promote atherosclerosis progression. Interestingly, SAA exerts anti-atherosclerosis effects by inhibiting the secretion of GRP78. Further mechanistic studies indicated that SAA upregulates the expression of lncRNA NR2F2-AS1, which reverses the abnormal localization of the KDEL receptor (KDELR) caused by inflammation. It promotes the homing of GRP78 from the Golgi apparatus to the endoplasmic reticulum rather than secreting outside the cell. SAA alleviates atherosclerosis by inhibiting GRP78 secretion via the lncRNA NR2F2-AS1-KDELR axis. The findings not only provide a new direction for the precise therapy of atherosclerosis based on secretory GRP78 but also elucidate the pharmacological mechanism of SAA against atherosclerosis, putting the foundation for further development and clinical application of SAA drugs. Increased GRP78 secretion of endothelial cells drives macrophage infiltration to promote atherogenesis. SAA upregulates the expression of lncRNA NR2F2-AS1, reverses the abnormal localization of KDELR, inhibits GRP78 secretion, and exerts anti-atherosclerosis effects in vivo. [Display omitted] • Intestinal-derived LPS stimulates endothelial cells to secrete more GRP78. • GRP78-induced monocyte/macrophages infiltration into the vascular intima drives the progression of atherosclerosis. • SAA exerts anti-atherosclerosis effects by inhibiting the secretion of GRP78, which was further verified in vivo. • Interaction of lncRNA NR2F2-AS1 with KDELR mediates the blockade of GRP78 secretion by SAA. [ABSTRACT FROM AUTHOR]

Chemoresistance is one of the difficulties in the treatment of colorectal cancer (CRC), and the enhanced stemness of tumor cells is the underlying contributing factor. Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) is a classical marker of CRC stem cells and can be an important potential target for CRC chemotherapy. Quinoa, a protein-rich plant, offers potential as a source of high-quality active peptides. Novelly, the study obtained quinoa protein hydrolysate (QPH) from whole quinoa grains by simulated digestion. In vivo experiments revealed that the tumor volume in the 5-FU+QPH group decreased from 145.90 ± 13.35 to 94.49 ± 13.05 mm 3 in the 5-FU group, suggesting that QPH enhances the chemosensitivity of CRC. Further, the most effective peptide QPH-FR from 631 peptides in QPH was screened by activity prediction, molecular docking, and experimental validation. Mechanistically, QPH-FR competitively suppressed the formation of the LGR5/RSPO1 complex by binding to LGR5, causing RNF43/ZNRF3 to ubiquitinate the FZD receptor, thereby suppressing the Wnt/β-catenin signaling pathway and exerting stemness inhibition. In summary, the study proposes that a novel peptide QPH-FR from quinoa elucidates the mechanism by which QPH-FR targets LGR5 to enhance chemosensitivity, providing theoretical support for the development of chemotherapeutic adjuvant drugs based on plant peptides.